Мера укрепления доверия "G"

Оборудование для производства вакцин

Vaccines contrate production (bulk) against diphtheria, tetanus, rabies, tick-borne encephalitis, mumps are produced in Marburg.
These products are formulated in Marburg. Final vaccines formulation and filling is performed at another GSK site.
Vaccines contrate (bulk) for Meningococcus meningitis serumgroup A is formulated and lyophilised in Marburg. Final packaging with formulated serumgroups C, W, Y is performed at another GSK site.

Hepatitis B (commissioned production, no own licence for marketing)

Clinical trial material only, no own licenses for marketing: Tuberculosis vaccine (recombinant and non-recombinant), Smallpox vaccine (recombinant), Ebola vaccine (recombinant), Bordetella vaccine, HIV vaccine (recombinant), Zika vaccine (recombinant), Typhus vaccine, RSV, Newcastle Disease Virus (Drug Substance, recombinant), Influenza A (PR8 vaccine).

Live Smallpox vaccines, Following Investigational Medicinal Products - live recombinant HIV vaccines, live recombinant Malaria vaccines, live recombinant and inactivated recombinant Filovirus vaccines, live recombinant Flavivirus vaccines, MERS-CoV vaccines, inactivated recombinant Lassa virus vaccine

Influenza virus vaccine for human immunisation purposes

expected to be approved this year for manufacture of live recombinant Ebola virus vaccines
(GMP inspection pending)